Amylyx upgraded to Strong Buy after positive phase 3 trial for avexitide in post-bariatric hypoglycemia

Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stoc...